Connor Clark & Lunn Investment Management Ltd. Purchases New Stake in Definitive Healthcare Corp. (NASDAQ:DH)

Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Definitive Healthcare Corp. (NASDAQ:DH - Free Report) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 114,552 shares of the company's stock, valued at approximately $512,000. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.10% of Definitive Healthcare at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in Definitive Healthcare by 1.5% during the first quarter. Vanguard Group Inc. now owns 4,535,377 shares of the company's stock worth $36,600,000 after purchasing an additional 67,068 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its position in Definitive Healthcare by 28.3% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 4,426,420 shares of the company's stock worth $24,168,000 after buying an additional 976,279 shares in the last quarter. Millennium Management LLC acquired a new position in shares of Definitive Healthcare during the 2nd quarter worth about $9,283,000. Granite Investment Partners LLC grew its holdings in shares of Definitive Healthcare by 22.5% in the 2nd quarter. Granite Investment Partners LLC now owns 884,872 shares of the company's stock valued at $4,831,000 after acquiring an additional 162,432 shares in the last quarter. Finally, 272 Capital LP bought a new stake in Definitive Healthcare during the second quarter worth about $3,480,000. 98.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently weighed in on DH. Morgan Stanley lowered their target price on shares of Definitive Healthcare from $9.00 to $5.00 and set an "equal weight" rating on the stock in a report on Tuesday, August 6th. BTIG Research started coverage on shares of Definitive Healthcare in a research note on Tuesday, September 17th. They issued a "buy" rating and a $7.00 target price for the company. Robert W. Baird lowered their price target on Definitive Healthcare from $6.00 to $5.00 and set a "neutral" rating on the stock in a research report on Wednesday, August 7th. Needham & Company LLC reaffirmed a "hold" rating on shares of Definitive Healthcare in a research report on Friday, November 8th. Finally, Deutsche Bank Aktiengesellschaft decreased their target price on Definitive Healthcare from $7.00 to $5.00 and set a "hold" rating on the stock in a report on Friday, August 9th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat.com, Definitive Healthcare has a consensus rating of "Hold" and an average target price of $5.81.

Definitive Healthcare Stock Performance

NASDAQ DH traded up $0.07 on Friday, reaching $4.73. The stock had a trading volume of 150,049 shares, compared to its average volume of 738,068. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.49 and a quick ratio of 2.49. The company has a market cap of $546.41 million, a P/E ratio of -1.53, a price-to-earnings-growth ratio of 3.44 and a beta of 1.33. The firm has a fifty day moving average of $4.35 and a two-hundred day moving average of $4.78. Definitive Healthcare Corp. has a 1-year low of $3.19 and a 1-year high of $10.62.

Definitive Healthcare Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.